Prostate cancer: Doing less might be more

Archives of Internal Medicine

Volumn 170, Issue 15, 2010, Pages 1397-1399

  Ablin, Richard J ^a   Sartor, Oliver ^b   Bennett, Charles L ^c  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c University of South Carolina   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

CANCER MORTALITY; CANCER SCREENING; CAUSE OF DEATH; COMORBIDITY; DIAGNOSTIC ERROR; DIAGNOSTIC VALUE; EARLY DIAGNOSIS; GROUPS BY AGE; HUMAN; LETTER; LIFE EXPECTANCY; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; SCREENING TEST; THERAPEUTIC ERROR; BLOOD; CANCER STAGING; HEALTH SURVEY; HOSPITALIZATION; IMMUNOLOGY; MALE; MASS SCREENING; METHODOLOGY; NOTE; PATHOLOGY; PROSTATE TUMOR; STATISTICS; UNNECESSARY PROCEDURE;

CAUSE OF DEATH; COMORBIDITY; HUMANS; MALE; MASS SCREENING; NEOPLASM STAGING; POPULATION SURVEILLANCE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SEVERITY OF ILLNESS INDEX; TUMOR MARKERS, BIOLOGICAL; UNNECESSARY PROCEDURES;

EID: 77955447408     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinternmed.2010.290     Document Type: Letter

References (11)

1. Bruchovsky N. Preface. In: Farnsworth WE, Ablin RJ, eds. The Prostate as an Endocrine Gland. Boca Raton, FL: CRC Press, Inc; 1990.
2. Raghavan D. Controversies in the management of localized prostate cancer: after the rhetoric. Oncology (Williston Park). 2009;23(10):833-835.
3. Bennett CL, Greenfield S, Aronow H, Ganz P, Vogelzang NJ, Elashoff R. Patterns of care related to age of men with prostate cancer. Cancer. 1991;67(10):2633-2641.
4. Ablin RJ, Soanes WA, Bronson P, Witebsky E. Precipitating antigens of the normal human prostate. J Reprod Fertil. 1970;22(3):573-574.
5. Ablin RJ, Haythorn MR. Screening for prostate cancer: controversy? what controversy? Curr Oncol. 2009;16(3):1-2.
6. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003;349(3):215-224. (Pubitemid 36859473)
7. Sakr WA, Grignon DJ, Crissman JD, et al. High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20-69: an autopsy study of 249 cases. In Vivo. 1994;8(3):439-443.
8. Klotz L, Danjoux C, Nam R, Loblaw A. Active surveillance for favorable risk prostate cancer: long-term follow-up in 453 patients [abstract 89]. Abstract presented at: 2009 Genitourinary Cancers Symposium; February 26-28, 2009; Orlando, FL.
9. Klotz L, Zhang L, Vesprini D, Loblaw A. Comparing PSA triggers for treatment formen with nonprogressive prostate cancer on active surveillance [abstract 13]. Abstract presented at: 2010 Genitourinary Cancers Symposium; March 5-7, 2010; San Francisco, CA.
10. Uchio EM, Aslan M, Wells CK, Calderone J, Concato J. Impact of biochemical recurrence in prostate cancer among US veterans. Arch Intern Med. 2010;170(15):1390-1395.
11. Freedland SJ, Humphreys EB, Mangold LA, et al. Death in patients with recurrent prostate cancer after radical prostatectomy: prostate-specific antigen doubling time subgroups and their associated contributions to allcause mortality. J Clin Oncol. 2007;25(13):1765-1771.